



Department of Health and Human Services  
MaineCare Services  
11 State House Station  
Augusta, Maine 04333-0011  
Tel.: (207) 287-2674; Fax: (207) 287-2675  
TTY Users: Dial 711 (Maine Relay)

## DUR COMMITTEE AGENDA

Date: Tuesday, June 14, 2016  
Time: 5:30PM to 8:30PM  
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

- 1) Call to Order
- 2) Introductions of New Committee Members
- 3) MaineCare Updates
- 4) Public Comments
- 5) Old Business
  - Review of Minutes
  - Follow up from February DUR meeting- Appropriate Testosterone Use Update
- 6) Closed Session
  - Drug Financial Information Review
- 7) New Business (open session)
  - A. Retro-DUR
    - Diabetes – appropriate utilization of angiotensin modulators in patients with diabetes and hypertension\*
  - B. HIV - PDL/Guideline review and recommendations
  - C. New Drug Review

Cinqair	Taltz	Prestalia
Descovy	Cabometyx	Xeljanz XR
Viberzi	Adzenys XR	Portrazza
Venclexta	Narcan NS	Bendeka
Sernivo	Vraylar	Opdivo
Otiprio	Odefsey	Darzalex
Spritam	Zembrace	
  - D. FDA Safety Alerts
    - Fluconazole Injection, USP, (in 0.9 Percent Sodium Chloride) 200mg per 100ml: Recall - Elevated Impurity  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm489316.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm489316.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
    - FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin  
[http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

- Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm491715.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm491715.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function  
[http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in Combination with other Cancer Medicines  
[http://www.fda.gov/Drugs/DrugSafety/ucm490618.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm490618.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA warns consumers about potential risks of using eye drops packaged in bottles with loose safety seals  
[http://www.fda.gov/Drugs/DrugSafety/ucm490693.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm490693.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- FDA advises health care professionals that counterfeit BiCNU has been discovered in some foreign countries  
[http://www.fda.gov/Drugs/DrugSafety/ucm500705.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm500705.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- Information on Clozapine  
[http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm497790.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm497790.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- Canagliflozin (Invokana, Invokamet): Drug Safety Communication - Clinical Trial Results Find Increased Risk of Leg and Foot Amputations  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm501565.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm501565.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498823.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498823.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- Brintellix (vortioxetine): Drug Safety Communication - Brand Name Change to Trintellix, to Avoid Confusion With Antiplatelet Drug Brilinta (ticagrelor)  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498607.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498607.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections  
[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500665.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500665.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)
- Nizoral (ketoconazole) Oral Tablets: Drug Safety Communication - Prescribing for Unapproved Uses including Skin and Nail Infections Continues; Linked to Patient Death  
<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm502073.htm>

E. Next Meeting (Tuesday, September 13, 2016)

F. Adjournment: 8:30PM